reason report
trap valu guid ep ep growth
bottom line see sell-off solid initi
guid beat nice revenu meet ep
handl includ prior year develop overdon reiter
op rate lower pt
see margin pressur ep growth re-acceler
headwind relat brand rebat guarante break open
gener aet experi rate start-up cost moder
offset continu weak reimburs pbm in-sourc
manag also confid exceed guid mm
synergi drive multi-year multi-billion dollar enterpris
cost save initi omnicar loss compris half pressur
seen retail/ltc oper incom guidanc also
moder potenti futur spin-off sale unlock valu
adjust ep includ aet
recur favor reserv develop ep
contempl re-acceler growth ep cfo
solid offer annual leverag
ratio improv oper leas
low oper leas lower pt
contempl price-to-earnings averag ep
beat modestli ep revenu ss sale growth
beat retail rx network specialti volum offset
modest front store miss in-lin pbm aet beat
consensu littl prior year develop
initi guid better suggest headlin given
reach expect ep above-consensu revenu
includ aet prior year develop given report chang
unclear releas consist histor
report practic aet
tailwind retail rx specialti growth aet
synergi enterpris cost save target multi-billion
dollar save multi-year period look pois continu
sever headwind look pois moder
drive growth acceler -- specif headwind relat
break open gener pbm rebat guarante weaker brand
cost offset continu price reimburs pressur
retail pbm segment in-sourc pbm
biz also offer potenti rebat headwind abat
price-to-earnings averag
ep
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu billion adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
adjust estim lower ep
align initi guidanc reflect potenti
aet recur prior period develop ep also align
guidanc reflect cadenc earn across
segment per manag commentari ep goe
align growth acceler transient headwind subsid re-
de-lever enabl strong gener cfo
solid offer annual
leverag ratio improv oper leas
low oper leas
hh drug rebat propos quit manag manag
confid disclosur mm rebat exposur
new guarante net model proactiv address hh
propos drug price reform
health offer option upsid phased-
within target geographi start houston tx offer potenti
attract econom across aet medic cost structur
improv store traffic sale growth beyond
lower price contempl
price-to-earnings averag ep
see sell-off solid initi guid beat nice revenu
meet ep handl includ prior year develop overdon reiter
op rate lower pt see margin pressur
ep growth re-acceler headwind relat brand rebat guarante
weak reimburs pbm in-sourc manag also confid exceed
guid mm synergi drive multi-year multi-billion dollar enterpris cost
save initi omnicar loss compris half pressur seen retail/ltc
oper incom guidanc also moder potenti futur spin-off sale
unlock valu adjust ep includ aet recur
favor reserv develop ep contempl re-acceler growth
ep cfo solid offer annual
leverag ratio improv oper leas low
oper leas pt contempl price-to-earnings averag
ep
beat modestli ep revenu ss sale growth beat retail rx
network specialti volum offset modest front store miss in-lin
pbm aet beat consensu littl prior year develop
unit mm except eps/aet earningsreport leerink estimatesstreetaccount estimatesreport yoyadj pharmaci oper corpor
compstore retail rx network specialti volum off-set modest front store miss
initi guid better suggest headlin given reach expect
ep above-consensu revenu includ aet prior year develop given
report chang unclear releas consist histor report
practic aet
guidanceitemscompanysvb leerinkconsensusnet oper net ep includ rxoper sevicesnet adj claim benefit /- corpor
headwind tailwind
half oi declin retail long-term driven omnicar busi tax reform investmentsa think perform retail contract impact omnicar well tax reform invest repres half contract clearli next signific driver larri describ around lower benefit gener boratto evp cfo health corp tx corpor
tailwind retail rx specialti growth aet synergi enterpris
cost save target multi-billion dollar save multi-year period look pois
continu
tailwind continu
see tailwind retail rx growth take market shareth good news retail busi win top line take market share front-end pharmaci busi reson consum grow share wallet consum take market share kevin hourican president- pharmaci corp retail pharmaci adjust oper incom grew solidli full year ur market-lead script growth increas pharmaci market share record decembereva boratto cfo corp confid exceed synergi target mmsignific synergi gener combin busi year stem elimin duplic corpor oper function purchas effici medic cost save includ formulari align synergi expect track exceed goal boratto cfo corp enterpris wide cost-reduct strategi start bear fruitin earli januari began plan new cost-reduct effort across enterpris go beyond previous announc product initi legaci compani target opportun neither compani would abl accomplish stand-alone effort addit near-term synergi work tie target track exceedlarri merlo presid ceo director corp corpor
synergi aet deal
sever headwind look pois moder drive growth acceler
-- specif headwind relat break open gener pbm rebat guarante
offset continu price reimburs pressur retail pbm segment
in-sourc pbm biz also offer potenti rebat headwind
abat combin caremark-aet go-to-market strategi
mani headwind set abat
mani headwind transitorya look transitori natur headwind think impact invest tax reform roll mid-year year look inflat impact rebat guarante peak roll end certainli expect omnicar perform stabil improv think contribut gener talk mani time go peak valley occur given year sit today look look like expect improv mani headwind transitori natur larri merlo presid ceo director health corp txgener headwind set improv heard us talk less valu break-open gener compar primarili due time launch lead slower progress break-open statu also gener launch compar singl sourc gener unabl optim profit exclus period result gener part headwind final see gener launch limit competit stay limit competit even exclus period expir driven mani factor includ manufactur complex regulatori approv timelin look forward base know today see improv robert chief oper offic evp health corp tx corpor
lower ep align initi guidanc reflect
potenti aet recur prior period develop ep also align guidanc
reflect cadenc earn across segment per manag commentari
ep goe align growth acceler transient headwind subsid re-
lower ep
cfo solid offer annual leverag ratio
improv oper leas low oper leas
consensussvb leerinksvb leerink oldconsensussvb leerinksvb leerink oldconsensusleerinksvb leerink oldoper revenu incom bp chang corpor
leverag improv oper leas oper
leas
manag confid disclosur mm rebat exposur new
guarante net model proactiv address hh propos drug price reform
debt paydown valu op leas adj debt op ebitda interest expens oper leas op leas ebitda leas debt/ebitda op calcul base number corpor
manag commentari recent hh propos
health phased-in within target geographi start houston tx offer
potenti attract econom across aet medic cost structur improv store traffic
sale growth beyond
recent hh propos appear manag sever solut alreadi placeso one concern fewer beneficiari sign part look estim cost billion year put taxpay hook brand pharma end profit windfal certainli readili avail solut commerci place appli medicar look potenti could work commerci client today reduc out-of-pocket cost pos rebat util prevent drug list think program like far better solut propos rule also talkedabout real-tim benefit tool caremark kevin got similar program retail pharmaci tool reduc out-of-pocket cost consum certainli weigh comment period concern rebat rule importantli believ appropri solut address root caus tri solv larri merlo presid ceo director health corp tx corpor
becom one-stop-shop consum healthcar need
believ front model could drive ebit
aetna member util save non aet member visit new prescript visitor purchas telehealth visit keep new clinician gross margin retail gross margin year revenu corpor
pt contempl price-to-earnings averag ep
incom pbm retail oper invest futur pharmaci ens incl pension oper oper net incom share growth revenu includ corpor
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings averag ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base absolut price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
price target base price-to-earnings averag ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
integr regulatori risk across merg ci esrx
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans price target base case
ep estim
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
pt contempl price-to-earnings averag ep
expect synergi across administr effici retail steerag aet member
benefit design chang floor rebat reduct store base distribut
 part polici drive upsid estim also multipl expans pt
underwrit risk aet asset trade peak margin commerci fulli
insur though medacorp commerci broker price survey give us confid
price environ remain appropri hard offer flat even potenti
modestli expand underwrit margin risk potenti futur margin compress
aet health insur even meaning given associ neg impact
debt ebitda load compani need focus debt
pay next month departur shawn guertin aet cfo
slate becom cfo make us less confid price postur
health insur book commenc new bulk compet
share gain commerci medicar advantag market
macroeconom risk risk macroeconom downturn higher
defens pbm sub sector given cyclic correl retail front store
sale employ data
regulatori risk convinc pbm add valu earn
low probabl threat potenti drug manufactur rebat elimin off-set
new busi model includ administr fee and/or perform guarante
expos pbm retail pharmaci busi compar
player pbm risk
execut integr risk face greater risk well given integr
pbm broader organ also transform agenda around
build retail front model amid risk leverag balanc sheet
e-commerce/amzn greater exposur eros sale on-line
channel well given exposur retail front store retail pharmaci e-
commerc though larg price retail multipl expect less like
pursu agenda becom pbm given associ integr clinic evid
base treatment guidelin integr provid network domin captiv pbm
model mega deal
remain posit reiter op rate month pt
contempl price-to-earnings averag ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yet yield adequ
return capit
pt reflect price-to-earnings ep
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
base post month turnaround rate outperform pt
contempl price-to-earnings averag ep
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
averag cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
averag ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
